National study finds decline in drug use–associated heart infections but growing share involves stimulants

· Medical Xpress

by University of Colorado Anschutz

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources


Temporal trends in national estimates of injection drug use-associated infective endocarditis hospitalizations by type of drug use, 2016–2022, National Inpatient Sample. Credit: Clinical Infectious Diseases (2026). https://doi.org/10.1093/cid/ciag607

A new national study found that hospitalizations for serious heart infections associated with drug use are declining after years of increases, driven largely by a decrease in opioid-associated cases.

Published today in Clinical Infectious Diseases, the study analyzed national hospitalization data from 2016 through 2022 to identify trends in drug use–associated infective endocarditis. Researchers identified more than 118,000 hospitalizations nationwide during the seven-year period. Hospitalizations peaked at approximately 18,700 in 2020, during the COVID-19 pandemic, before declining by 18% to about 15,300 in 2022.

Infective endocarditis is a potentially life-threatening infection that occurs when bacteria or other germs enter the bloodstream and infect the inner lining or valves of the heart. The infection, which can occur when people inject drugs, can cause permanent heart damage, require lengthy hospital stays or lead to death.

"Our goal was to provide an updated national picture of these serious infections, which often affect younger adults in their 30s," said the paper's first author, Paul Christine, M.D., Ph.D., assistant professor of medicine at the University of Colorado Anschutz. "With opioid injection historically accounting for a large share of these infections, we wanted to understand whether greater availability of addiction treatments and harm reduction services, along with changes in how people use drugs, may have influenced hospitalization trends nationwide."

Potential reasons behind the decline

The researchers hypothesized several possible factors contributing to the decline. One possible explanation is expanded access to addiction treatment and harm reduction services for opioid use, such as access to sterile syringes and education about safer drug use practices, as well as greater efforts to connect people with opioid use disorder to medications that can help them enter recovery.

Another possible explanation is a shift from injecting drugs to smoking them. Because injecting drugs can introduce bacteria into the bloodstream, fewer people injecting may be helping reduce the risk of developing these serious infections.

Stimulants outnumbered opioid cases in parts of the country

The researchers also pointed out another key finding: while opioid-associated hospitalizations are declining, stimulants such as methamphetamine and cocaine are accounting for a growing share of these serious infections, particularly in the western part of the United States.

  • The researchers estimated a 59% probability of stimulant-involved infective endocarditis in the Pacific region, compared to 34% in New England.
  • Nationwide, in 2016, approximately 37% of drug use–associated endocarditis hospitalizations involved stimulants, either alone or in combination with opioids. By 2022, that proportion had increased to nearly 47%.

"I believe the problem isn't simply that stimulants are becoming more prominent. It's that the health care system currently has fewer effective tools to treat stimulant use disorder than opioid use disorder," said Christine.

He explained that while significant attention and resources have rightly been devoted to treating opioid use disorder, comparatively fewer efforts have focused on engaging and treating people who use stimulants. Additionally, unlike opioid use disorder, which has several effective medication options, there are currently no FDA-approved medications specifically for stimulant use disorder.

Christine and his colleagues want to next explore more effective hospital-based interventions for patients who use stimulants, with a focus on helping them access addiction treatment and connect with ongoing care after discharge.

They also want to investigate next whether similar declines are occurring in other serious infections associated with drug use, including skin, soft tissue and bone infections.

Publication details

Changing National and Regional Trends in Drug Use-Associated Infective Endocarditis From 2016 to 2022, Clinical Infectious Diseases (2026). doi.org/10.1093/cid/ciag607

Journal information: Clinical Infectious Diseases

Key medical concepts

Analgesics, Opioid

Clinical categories

Infectious diseasesCardiology Provided by University of Colorado Anschutz Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: National study finds decline in drug use–associated heart infections but growing share involves stimulants (2026, October 27) retrieved 27 October 2026 from https://medicalxpress.com/news/2026-10-national-decline-drug-useassociated-heart.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.